靶向核仁素改善弥漫性大B细胞淋巴瘤生存
研究鉴定核仁素为拓扑异构酶IIα(TopIIA)的新结合伙伴,沉默核仁素使DLBCL细胞对多柔比星/依托泊苷敏感并促进DNA损伤与凋亡;核仁素低表达者接受R-CHOP方案治疗的90个月估计生存率为70%,高表达者为12%(P<0.0001)。
要点
- 核仁素与TopIIA的RNA结合域3结合,该相互作用对阻断DNA损伤和凋亡至关重要。
- 沉默核仁素增强依托泊苷存在下TopIIA-DNA可切割复合物的形成,但降低TopIIA解链活性。
- 核仁素抑制剂AS1411或N6L与多柔比星联用可降低DLBCL细胞存活。
核心结论
- 核仁素是TopIIA的新结合伙伴,其沉默使DLBCL细胞对TopIIA靶向药物敏感,并在核仁素敲低细胞中重建核仁素表达可阻止TopIIA靶向药物诱导的凋亡。
- 核仁素低水平 versus 高水平在R-CHOP方案治疗的DLBCL患者中预测90个月估计生存率为70% versus 12%(P<0.0001),作者认为这些发现具有临床重要性。
研究设计与样本
- 研究为体外细胞实验,使用DLBCL细胞系,未报告样本量。
主要发现
- 沉默核仁素并用多柔比星处理DLBCL细胞增强H2AX磷酸化(γH2AX,DNA损伤标志物)并允许DNA片段化。
- 核仁素与TopIIA的结合定位在核仁素的RNA结合域3,该相互作用对阻断DNA损伤和凋亡至关重要。
- 沉默核仁素降低TopIIA解链活性,但增强依托泊苷存在下TopIIA-DNA可切割复合物的形成。
- 核仁素抑制剂AS1411或N6L与多柔比星联用降低DLBCL细胞存活。
- 在R-CHOP方案治疗的DLBCL患者中,核仁素低水平 versus 高水平预测90个月估计生存率为70% versus 12%(P<0.0001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anthracyclines have been a cornerstone in the cure of diffuse large B-cell lymphoma (DLBCL) and other hematological cancers. The ability of anthracyclines to eliminate DLBCL depends on the presence of topoisomerase-II-alpha (TopIIA), a DNA repair enzyme complex. We identified nucleolin as a novel binding partner of TopIIA. Abrogation of nucleolin sensitized DLBCL cells to TopIIA targeting agents (doxorubicin/etoposide). Silencing nucleolin and challenging DLBCL cells with doxorubicin enhanced the phosphorylation of H2AX (γH2AX-marker of DNA damage) and allowed DNA fragmentation. Reconstitution of nucleolin expression in nucleolin-knockdown DLBCL cells prevented TopIIA targeting agent-induced apoptosis. Nucleolin binding to TopIIA was mapped to RNA-binding domain 3 of nucleolin, and this interaction was essential for blocking DNA damage and apoptosis. Nucleolin silencing decreased TopIIA decatenation activity, but enhanced formation of TopIIA-DNA cleavable complexes in the presence of etoposide. Moreover, combining nucleolin inhibitors: aptamer AS1411 or nucant N6L with doxorubicin reduced DLBCL cell survival. These findings are of clinical importance because low nucleolin levels versus high nucleolin levels in DLBCL predicted 90-month estimated survival of 70% versus 12% (P<0.0001) of patients treated with R-CHOP-based therapy.
引用
- Jain N, Zhu H, Khashab T, et al. Targeting nucleolin for better survival in diffuse large B-cell lymphoma. Leukemia. 2017. PMID: 28690315. doi:10.1038/leu.2017.215
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。